Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Reblozyl (luspatercept-aamt)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS, Merck (MSD)

Drug class:

TGFβ inhibitor

Related drugs:

No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A1 - Approval luspatercept-aamt Sensitive : A1	luspatercept-aamt Sensitive: A1 - Approval luspatercept-aamt Sensitive : A1
CALR mutation	Myelodysplastic Syndrome	CALR mutation	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
SF3B1 mutation	Myelodysplastic Syndrome	SF3B1 mutation	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
SF3B1 K700E	Myelodysplastic Syndrome	SF3B1 K700E	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: C3 – Early Trials luspatercept-aamt Sensitive : C3	luspatercept-aamt Sensitive: C3 – Early Trials luspatercept-aamt Sensitive : C3